IMPACT OF ANGIOTENSIN-CONVERTING ENZYME GENE POLYMORPHISM ON THE DEVELOPMENT OF INSULIN RESISTANCE SYNDROME
https://doi.org/10.17650/1818-8338-2013-2-14-17
Abstract
Objective: to analyze the distribution of components of insulin resistance (IR) syndrome and to study the frequency of their combinations in relation to the genotypes and allelic variants of the angiotensin-converting enzyme (ACE) gene.
Subjects and methods. A group of clinically healthy patients (50 women and 42 men) with different genotypes of the ACE gene was examined.
The distribution of IR syndrome components and the frequency of their combinations were analyzed in relation to the genotypes and allelic
variants of the ACE gene.
Results. A group of D allele carriers compared to A allele ones showed a pronounced tendency for the frequency of IR to reduce due to the
higher proportion of patients with complete IR syndrome. This observation becomes statistically significant in the assessment of homozygous variants of the ACE gene. At the same time dyslipidemia and hypertension in the presence of IR significantly more frequently occurred in patients with the DD genotype than in those with genotype II.
Conclusion. There was a marked predominance of the manifestations of IR syndrome with a complete set of components in the DD genotypic
group, which confirms the significant strong association between ACE gene polymorphism and IR syndrome.
About the Authors
G. E. Roitberg
N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
Zh. V. Dorosh
N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
E. V. Aksenov
N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
T. I. Ushakova
N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
References
1. The IDF worldwide definition of the metabolic syndrome. http://www.idf.org/metabolic-syndrome.
2. Anderson P.J., Critchley J.A., Chan J.C. et al. Factor analysis of the metabolic syndrome: obesity vs insulin resistance as the central abnormality. Int J Obes Relat Metab Disord 2001;25(12):1782–8.
3. Carr D.B., Utzschneider K.M., Hull R.L. et al. Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. Diabetes 2004;53(8):2087–94.
4. Метаболический синдром. Под ред. член-корр. РАМН Г.Е. Ройтберга. М.: МЕДпресс-информ, 2007.
5. de Kloet A.D., Krause E.G., Woods S.C. The renin angiotensin system and the metabolic syndrome. Physiol Behav 2010;100(5):525–34.
6. Lucius R., Gallinat S., Busche S. et al. Beyond blood pressure: new roles for angiotensin II. Cell Mol Life Sci 1999;56(11–12);1008–19.
7. Johnston C.I., Risvanis J. Preclinical pharmacology of angiotensin II receptor antagonists: update and outstanding issues. Am J Hypertens 1997;10(12 Pt 2):306S–10S.
8. Chung O., Stoll M., Unger T. Physiologic and pharmacologic implications of AT1 versus AT2 receptors. Blood Press Suppl 1996;5(2):47–52.
9. Mattei M.G., Hubert C., Alhenc-Gelas F. et al. Angiotensin-I converting enzyme gene is on chromosome 17. Cytogenet Cell Genet 1989;51:1041–5.
10. Balkau B., Charles M.А., Drivsholm T. et al. Frequency of the WHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndrome. Diabetes Metab 2002;28(5):364–76.
11. Метаболический синдром. Под ред. В. Фонсеки. М.: Практика, 2011.
12. Nesto R.W. The relation of insulin resistance syndromes to risk of cardiovascular disease. Rev Cardiovasc Med 2003;4(6):S11–8.
13. Grundy S.M. Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds. J Am Coll Cardiol 2006;47(6):1093–100.
14. De Ferranti S.D., Gauvreau K., Ludwig D.S. et al. Prevalence of the metabolic syndrome in American adolescents: findings from the Third National Health and Nutrition Examination Survey. Circulation 2004;110(16):2494–7.
15. Israelian-Konaraki Z., Reaven P.D. Peroxisome proliferator-activated receptor-alpha and atherosclerosis: from basic mechanisms to clinical implications. Cardiology 2005;103(1):1–9.
Review
For citations:
Roitberg G.E., Dorosh Zh.V., Aksenov E.V., Ushakova T.I. IMPACT OF ANGIOTENSIN-CONVERTING ENZYME GENE POLYMORPHISM ON THE DEVELOPMENT OF INSULIN RESISTANCE SYNDROME. The Clinician. 2013;7(2):14-17. (In Russ.) https://doi.org/10.17650/1818-8338-2013-2-14-17
Views:
962
Email this article 